February 2019

Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center, is currently conducting more than 120 research studies, including clinical trials of targeted therapies and novel immunotherapy approaches.

Immunotherapy studies for triple-negative breast cancer

Emerging research is finding that immunotherapy may extend survival for some women with triple-negative breast cancer. At Providence Cancer Institute, two Phase 3 immunotherapy studies are open now for women with metastatic and non-metastatic TNBC : A study of sacituzumab govitecan for metastatic TNBC after two prior treatments (ASCENT) A study of pembrolizumab as adjuvant therapy for patients with residual TNBC or positive lymph nodes after chemotherapy

Read More About These Studies

All current open studies:

Brain Cancer Breast Cancer Gastrointestinal Cancers  Genitourinary Cancers Gynecologic Cancers

Head and Neck Cancers Hematologic Cancers Lung Cancer Melanoma Phase 1 Trials

Find additional studies for many types of cancer in Multiple Tumor Types .

New studies are posted frequently - please check our  website  for a complete list of our current studies. For more information, call 503-215-2614.

Refer A Patient

Email Our Team

See All Open Studies

Earle A. Chiles Research Institute

Sign up to receive this newsletter

‌ ‌ ‌